StockNews.AI
CTKB
StockNews.AI
23 hrs

Cytek® Biosciences Expands European Presence with New Facility in Amsterdam to Better Serve Customers and Drive Growth

1. CTKB relocates European headquarters to Amsterdam's Life Sciences District. 2. Expansion increases operational footprint by over 40% for better service. 3. New facility enhances customer training and FSP technology utilization. 4. Strategic move is aimed at boosting CTKB's reagent business significantly. 5. CEO emphasizes commitment to EMEA region for long-term growth.

11m saved
Insight
Article

FAQ

Why Bullish?

The relocation and expansion signal strong growth potential. Investments in Europe can lead to increased revenue similar to past expansions in the U.S.

How important is it?

The article discusses strategic expansions and operational enhancements that directly align with CTKB's growth strategies, making it significant to investors.

Why Long Term?

The operational improvements and facility enhancements will likely translate into sustained growth over several quarters, as seen in historical trends with similar companies expanding operational capacities.

Related Companies

BDXMGBILMN
FREMONT, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- In a move that strengthens its European operations and enhances service for its customers, spectral flow cytometry leader Cytek Biosciences, Inc. (Nasdaq: CTKB) today announced the relocation of its European headquarters to a new facility in Amsterdam’s Life Sciences District. This relocation is an expansion, which reflects Cytek’s commitment to the EMEA region and highlights the company’s ongoing investment in delivering world-class solutions, training, and support to researchers and clinicians worldwide. The new site houses Cytek European offices and warehouse, which has increased the footprint by more than 40%, with a dedicated customer service and training center. The Training Center offers a fully functional lab environment, enabling researchers to receive hands-on training with Cytek instruments. This ensures scientists can maximize the potential of Cytek’s Full Spectrum Profiling™ (FSP®) technology to unlock high-dimensional data and enable laboratories to achieve more with fewer resources. The success of Cytek’s reagent business is one of the major drivers of this expansion, signaling its importance to Cytek’s global growth and innovation. As part of a strategic initiative to advance its reagent business, Cytek has transitioned warehouse operations in-house. This strengthens operational oversight, ensuring the highest standards of quality and control across the supply chain. The approach enhances organizational agility, improves operational efficiency, and accelerates turnaround times, delivering a consistent and dependable experience for customers. “Europe has been a key region in Cytek’s global growth journey, and we are making investments to strengthen our presence there,” said Wenbin Jiang, Ph.D., CEO of Cytek Biosciences. “The new Amsterdam facility expands our capabilities across the EMEA region, enabling us to more efficiently deliver solutions and services that advance scientific understanding, accelerate data-driven decision-making, and foster innovation.” For more information, please visit https://cytekbio.com/. About Cytek Biosciences, Inc.Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP®) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis® and Guava® brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at www.cytekbio.com. Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union). Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc. In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn page and X account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. All statements other than statements of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. These forward-looking statements include statements regarding Cytek’s business strategies, product plans and expectations and market opportunities, including but not limited to, Cytek’s future investment in its EMEA operations; Cytek’s ability to enhance its organizational agility and improve its operational efficiency; and future growth of Cytek’s reagents business. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management. These statements also deal with future events and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Factors that could cause actual results to differ materially include global geopolitical, economic and market conditions; Cytek’s ability to manage the impacts of recent and future export controls and licensing requirements, tariffs and NIH funding policies on its business; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek’s ability to accurately forecast customer demand and adoption of its products; Cytek’s ability to recognize the anticipated benefits of collaborations; Cytek’s dependence on certain sole and single source suppliers; competition; market acceptance of Cytek’s current and potential products; Cytek’s ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and hire and retain key employees; Cytek’s ability to manufacture its products in high-quality commercial quantities successfully and consistently to meet demand; Cytek’s ability to increase penetration in its existing markets and expand into adjacent markets; Cytek’s ability to secure additional distributors or maintain good relationships with its existing distributors; Cytek’s ability to successfully develop and introduce new products; Cytek’s ability to maintain, protect and enhance its intellectual property; Cytek’s ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations; and foreign currency exchange impacts. You should refer to the section entitled “Risk Factors” set forth in Cytek’s Quarterly Report on Form 10-Q filed on August 6, 2025 with the SEC, and other filings Cytek makes with the SEC from time to time for a discussion of important factors that may cause actual results to differ materially from those expressed or implied by Cytek’s forward-looking statements. Although Cytek believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the events and circumstances reflected in the forward-looking statements will occur. The forward-looking statements in this press release are based on information available to Cytek as of the date hereof, and Cytek disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Cytek’s as of any date subsequent to the date of this press release. Media Contact:Stephanie OlsenLages & Associates(949) 453-8080stephanie@lages.com Investor Contact:Paul GoodsonHead of Investor RelationsCytek Biosciencespgoodson@cytekbio.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3c6e0774-3ea5-4bb7-b982-85f249ca52e9 Cytek European Facility Cytek’s new facility in Amsterdam, The Netherlands, expands the company’s capacity to meet the growi...

Related News